KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Receivables: 2017-2024

Historic Receivables for BeOne Medicines (ONC) over the last 8 years, with Dec 2024 value amounting to $676.3 million.

  • BeOne Medicines' Receivables rose 51.71% to $863.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 billion, marking a year-over-year increase of 59.89%. This contributed to the annual value of $676.3 million for FY2024, which is 87.98% up from last year.
  • Latest data reveals that BeOne Medicines reported Receivables of $676.3 million as of FY2024, which was up 87.98% from $359.8 million recorded in FY2023.
  • BeOne Medicines' Receivables' 5-year high stood at $676.3 million during FY2024, with a 5-year trough of $73.1 million in FY2020.
  • Its 3-year average for Receivables is $404.1 million, with a median of $359.8 million in 2023.
  • As far as peak fluctuations go, BeOne Medicines' Receivables spiked by 568.22% in 2021, and later tumbled by 63.90% in 2022.
  • BeOne Medicines' Receivables (Yearly) stood at $73.1 million in 2020, then surged by 568.22% to $488.2 million in 2021, then plummeted by 63.90% to $176.2 million in 2022, then soared by 104.17% to $359.8 million in 2023, then spiked by 87.98% to $676.3 million in 2024.